LINK Medical welcomes the announcement that OncoZenge has received European regulatory approval to initiate its pivotal Phase III clinical trial of BupiZenge™, a novel treatment for oral pain in cancer supportive care.
The randomized, multi‑center Phase III study (BEAM‑Pain, BZ003) will evaluate the efficacy and safety of BupiZenge™ in patients with radiotherapy‑induced oral mucositis. LINK Medical acts as the clinical Contract Research Organization (CRO), supporting the trial execution across sites in Sweden, Norway, Denmark, and Germany.
“Strong collaboration between sponsor, sites, and partners is essential for success,” says Tahmina Haider, CPM LINK Medical.“We are proud to work closely with OncoZenge, contributing our clinical operations experience to help advance this important program for patients with significant unmet needs.”
With more than 30 years of experience as a Nordic full‑service CRO, LINK Medical supports pharmaceutical and medical device companies throughout the clinical development lifecycle. By working in close partnership with sponsors, LINK Medical helps ensure high‑quality execution and efficient progress from regulatory approval to patient enrollment and beyond.
